RAPS PRACTICE EXAM
RAPS PRACTICE EXAM NEWEST 2025/2026 COMPLETE
QUESTIONS AND CORRECT ANSWERS (VERIFIED ANSWERS)
|ALREADY GRADED A+||BRAND NEW VERSION!!
The FDA has published in the Federal Register a notice on the issuance of a new
draft guidance covering the testing of the device type manufactured by your
company. You lead a cross-functional team in the review of the draft guidance,
and it is the opinion of the team that the guidance contains assumptions that do
not adequately consider the technology used in the design of your devices. What
is the BEST option for addressing this situation?
a) Work with the cross-functional team to prepare comments and submit to FDA
on Regulations.gov within the stated comment period
b) Notify executive management that the new guidance might impact your
devices and discuss possible actions.
c) Email DICE to request written exemption from the guidance requirements.
d) Prepare an internal memo with a rationale for why the draft guidance is
unsuitable and propose alternative approaches.
a) Work with the cross-functional team to prepare comments and submit to FDA
on Regulations.gov within the stated comment period
Explanation:
The most effective way to address issues with draft guidance is to prepare and
submit comments through the formal public comment process. This allows you to
provide feedback directly to the FDA and suggest improvements or clarifications
based on your device's technology.
A device is considered misbranded if:
a) A device's established name (if applicable) or usual name is not properly
labeled
1|Page
, RAPS PRACTICE EXAM
b) The device is commercially distributed without FDA clearance or approval
c) Does not contain adequate directions for use.
d) All of the above
d) All of the above
Explanation:
A device is considered misbranded if it fails to meet any of these criteria: proper
labeling with the established or usual name, obtaining necessary FDA clearance or
approval before distribution, and including adequate directions for use.
The elements of an effective postmarket cybersecurity program, consistent with
the NIST Framework for Improving Critical Infrastructure Cybersecurity, and
recommended by FDA are the following:
a) Design, Protect Detect, Communicate, and Recover
b) Design, Analyze, Control, Respond, and Maintain
c) Identify, Investigate, Mitigate, Communicate, and Recover
d) Identify, Protect, Detect, Respond, and Recover
d) Identify, Protect, Detect, Respond, and Recover
Explanation:
The NIST Framework for Improving Critical Infrastructure Cybersecurity, which is
also recommended by the FDA, outlines the core functions of an effective
cybersecurity program: Identify, Protect, Detect, Respond, and Recover. These
functions help organizations manage cybersecurity risks to their systems.
You are the regulatory compliance expert in the organization and a re required to
suggest the mechanism to successfully achieve conformity to QMS, in regard to
identifying potential compliance issues. Which of the following is the LEAST
effective option?
a) Conducting internal audits against applicable regulations and standards
b) Regularly reviewing FDA Warning Letters issued to other companies
2|Page
, RAPS PRACTICE EXAM
c) Listening to podcasts on medical device industry compliance trends
d) Using a CAPA system, investigating potential internal compliance issues
c) Listening to podcasts on medical device industry compliance trends
Explanation:
While listening to podcasts can be informative, it is the least effective option for
achieving conformity to QMS. Internal audits, reviewing FDA Warning Letters, and
using a CAPA system are more direct and actionable methods for identifying and
addressing potential compliance issues.
A clinical trial of a medical device can begin how many days after notification is
sent to the Competent Authority?
a) 30 days
b) 45 days
c) 60 days
d) As soon as Ethical Committee approval is received
c) 60 days
Explanation:
In many regulatory jurisdictions, including the European Union, a clinical trial of a
medical device can begin 60 days after the notification is sent to the Competent
Authority, provided there are no objections, and ethical committee approval has
been obtained.
The Declaration of Conformity supporting the CE marking of a Class I medical
device includes all of the following EXCEPT:
a) The signature of the Notified Body
b) Identification of the directives according to which the device conforms
c) The manufacturer's name and address
d) Product information (name, type, or model number)
3|Page
, RAPS PRACTICE EXAM
a) The signature of the Notified Body
Explanation:
For Class I medical devices, the Declaration of Conformity does not require the
signature of a Notified Body. Notified Body involvement is typically required for
higher-risk classes of devices.
Which of the following is required for all medical devices?
a) EC-type examination certificate
b) Multilanguage labelling
c) Notified Body involvement
d) Technical documentation
d) Technical documentation
Explanation:
Technical documentation is required for all medical devices, regardless of their
classification. It includes information necessary to demonstrate that the device
complies with the relevant regulatory requirements. The other options (EC-type
examination certificate, multilanguage labeling, and Notified Body involvement)
are not universally required for all devices.
What does a regulatory professional need to address when preparing an internal
audit plan?
a) The audit scope, importance of the process, findings from previous audits, and
selection of auditors
b) The audit scope, findings from previous audits, selection of auditors, and
follow-up activities and actions taken with verifications
c) The findings from previous audits, selection of auditors, and follow-up activities
and actions taken with verifications
d) The importance of the process, findings from previous audits, and selection of
auditors
4|Page
RAPS PRACTICE EXAM NEWEST 2025/2026 COMPLETE
QUESTIONS AND CORRECT ANSWERS (VERIFIED ANSWERS)
|ALREADY GRADED A+||BRAND NEW VERSION!!
The FDA has published in the Federal Register a notice on the issuance of a new
draft guidance covering the testing of the device type manufactured by your
company. You lead a cross-functional team in the review of the draft guidance,
and it is the opinion of the team that the guidance contains assumptions that do
not adequately consider the technology used in the design of your devices. What
is the BEST option for addressing this situation?
a) Work with the cross-functional team to prepare comments and submit to FDA
on Regulations.gov within the stated comment period
b) Notify executive management that the new guidance might impact your
devices and discuss possible actions.
c) Email DICE to request written exemption from the guidance requirements.
d) Prepare an internal memo with a rationale for why the draft guidance is
unsuitable and propose alternative approaches.
a) Work with the cross-functional team to prepare comments and submit to FDA
on Regulations.gov within the stated comment period
Explanation:
The most effective way to address issues with draft guidance is to prepare and
submit comments through the formal public comment process. This allows you to
provide feedback directly to the FDA and suggest improvements or clarifications
based on your device's technology.
A device is considered misbranded if:
a) A device's established name (if applicable) or usual name is not properly
labeled
1|Page
, RAPS PRACTICE EXAM
b) The device is commercially distributed without FDA clearance or approval
c) Does not contain adequate directions for use.
d) All of the above
d) All of the above
Explanation:
A device is considered misbranded if it fails to meet any of these criteria: proper
labeling with the established or usual name, obtaining necessary FDA clearance or
approval before distribution, and including adequate directions for use.
The elements of an effective postmarket cybersecurity program, consistent with
the NIST Framework for Improving Critical Infrastructure Cybersecurity, and
recommended by FDA are the following:
a) Design, Protect Detect, Communicate, and Recover
b) Design, Analyze, Control, Respond, and Maintain
c) Identify, Investigate, Mitigate, Communicate, and Recover
d) Identify, Protect, Detect, Respond, and Recover
d) Identify, Protect, Detect, Respond, and Recover
Explanation:
The NIST Framework for Improving Critical Infrastructure Cybersecurity, which is
also recommended by the FDA, outlines the core functions of an effective
cybersecurity program: Identify, Protect, Detect, Respond, and Recover. These
functions help organizations manage cybersecurity risks to their systems.
You are the regulatory compliance expert in the organization and a re required to
suggest the mechanism to successfully achieve conformity to QMS, in regard to
identifying potential compliance issues. Which of the following is the LEAST
effective option?
a) Conducting internal audits against applicable regulations and standards
b) Regularly reviewing FDA Warning Letters issued to other companies
2|Page
, RAPS PRACTICE EXAM
c) Listening to podcasts on medical device industry compliance trends
d) Using a CAPA system, investigating potential internal compliance issues
c) Listening to podcasts on medical device industry compliance trends
Explanation:
While listening to podcasts can be informative, it is the least effective option for
achieving conformity to QMS. Internal audits, reviewing FDA Warning Letters, and
using a CAPA system are more direct and actionable methods for identifying and
addressing potential compliance issues.
A clinical trial of a medical device can begin how many days after notification is
sent to the Competent Authority?
a) 30 days
b) 45 days
c) 60 days
d) As soon as Ethical Committee approval is received
c) 60 days
Explanation:
In many regulatory jurisdictions, including the European Union, a clinical trial of a
medical device can begin 60 days after the notification is sent to the Competent
Authority, provided there are no objections, and ethical committee approval has
been obtained.
The Declaration of Conformity supporting the CE marking of a Class I medical
device includes all of the following EXCEPT:
a) The signature of the Notified Body
b) Identification of the directives according to which the device conforms
c) The manufacturer's name and address
d) Product information (name, type, or model number)
3|Page
, RAPS PRACTICE EXAM
a) The signature of the Notified Body
Explanation:
For Class I medical devices, the Declaration of Conformity does not require the
signature of a Notified Body. Notified Body involvement is typically required for
higher-risk classes of devices.
Which of the following is required for all medical devices?
a) EC-type examination certificate
b) Multilanguage labelling
c) Notified Body involvement
d) Technical documentation
d) Technical documentation
Explanation:
Technical documentation is required for all medical devices, regardless of their
classification. It includes information necessary to demonstrate that the device
complies with the relevant regulatory requirements. The other options (EC-type
examination certificate, multilanguage labeling, and Notified Body involvement)
are not universally required for all devices.
What does a regulatory professional need to address when preparing an internal
audit plan?
a) The audit scope, importance of the process, findings from previous audits, and
selection of auditors
b) The audit scope, findings from previous audits, selection of auditors, and
follow-up activities and actions taken with verifications
c) The findings from previous audits, selection of auditors, and follow-up activities
and actions taken with verifications
d) The importance of the process, findings from previous audits, and selection of
auditors
4|Page
